2025 ADC Industry Insights: Three Key Trends
2025 marks a breakout year for ADCs, with record clinical activity, the rapid emergence of novel modalities, and our first approvals As of Jan 2026, the global ADC pipeline has reached 2,334 assets. While the ADC field continues to grow rapidly, the pattern of growth is changing.
1. ADC Development Enters an Acceleration Phase
• Clinical activity is accelerating, with 130 ADCs entering the clinic in 2025 (+49% YoY).
• Pipeline expansion is accelerating, with 518 new ADC assets initiated in 2025.
This means: ADC development is shifting from feasibility to requiring efficient execution.
2. Rise of Novel ADC Modalities
Growth differs markedly: Novel ADCs are growing at +88% YoY vs. +20% for tradi- tional ADCs. AOCs and dual-payload ADCs lead, both exceeding 100% growth. ADC design is evolving from the classic antibody + cytotoxic payload model toward next-generation formats:
Development is becoming more complex, with rising technical barriers.
3.Payload Mechanisms Define Differentiation
At the clinical stage, payload strategies remain highly concentrated, primarily around topoisomerase I inhibitors and tubulin inhibitors.
This concentration is increasing homogeneity across pipelines, making new payload mechanisms essential for differentiation.
All data sourced from the Beacon database.
Development challenges are also shifting:
In this context, end-to-end integration is becoming a core competitive advantage.
Integrated, one-stop ADC CDMOs are becoming the preferred approach.
At ChemExpress, we offer integrated capabilities across ADC development:
